Trial Profile
Investigation of clinical efficacy of treat and extend regimen with intravitreal aflibercept in patients with ranibizumab resistant polypoidal choroidal vasculopathy (PCV).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Therapeutic Use
- 16 May 2017 New trial record